NasdaqCM - Delayed Quote USD

Evaxion A/S (EVAX)

2.9300 -0.1500 (-4.87%)

At close: October 30 at 4:00:01 PM EDT

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Evaxion receives International Prix Galien Award for AI-Immunology™ as best digital health solution

GlobeNewswire 1d ago

EVAX
-4.87%
Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01

GlobeNewswire 8d ago

EVAX
-4.87%
European Equities Traded in the US as American Depositary Receipts Advance in Tuesday Trading

PREMIUM
MT Newswires 11d ago

EVAX
-4.87%
ARGX

DBVT
Evaxion stock surges on 3-year melanoma vaccine trial data

Investing.com 12d ago

EVAX
-4.87%
Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01

GlobeNewswire 12d ago

EVAX
-4.87%
Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting

GlobeNewswire 29d ago

EVAX
-4.87%
Evaxion AS (EVAX) (Q2 2026) Earnings Call Highlights: Strong EVX-01 Data and Field Validation ...

GuruFocus.com 2mo ago

EVAX
-4.87%
Evaxion announces business update and second quarter 2026 financial results

GlobeNewswire 2mo ago

EVAX
-4.87%
Evaxion to announce business update and second quarter 2026 financial results on August 20, 2026

GlobeNewswire 2mo ago

EVAX
-4.87%
^IXIC
European Equities Traded in the US Rise in Thursday Trading

PREMIUM
MT Newswires 2mo ago

EVAX
-4.87%
NVO

BTI
Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026

GlobeNewswire 3mo ago

EVAX
-4.87%
Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1

GlobeNewswire 3mo ago

EVAX
-4.87%

Performance Overview

Return	EVAX	MSCI WORLD (^990100-USD-STRD)
YTD	-38.70%	+9.75%
1-Year	-49.13%	+10.75%
3-Year	-93.73%	+75.63%

U.S. markets closed

Evaxion A/S (EVAX)

Evaxion receives International Prix Galien Award for AI-Immunology™ as best digital health solution

Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01

European Equities Traded in the US as American Depositary Receipts Advance in Tuesday Trading

Evaxion stock surges on 3-year melanoma vaccine trial data

Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01

Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting

Evaxion AS (EVAX) (Q2 2026) Earnings Call Highlights: Strong EVX-01 Data and Field Validation ...

Evaxion announces business update and second quarter 2026 financial results

Evaxion to announce business update and second quarter 2026 financial results on August 20, 2026

European Equities Traded in the US Rise in Thursday Trading

Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026

Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1